Further financing at Mironid to support lead program through IND-enabling studies for ADPKD
Sep. 13, 2023
Mironid Ltd. has announced an extension of its series A financing round to support its development of small-molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The company will use the proceeds of the financing to advance its lead discovery program through IND-enabling studies.